Review of theories on development of ovarian cancer. Leptin as a potential agent engaged in carcinogenesis;Przegla̧d teorii rozwoju raka jajnika. Leptyna jako potencjalny czynnik biora̧cy udział w karcynogenezie

Nowotwory

Volumn 57, Issue 5, 2007, Pages 518-523

  Markowska, Anna ^a,b  

^a Klinika Perinatologii I Chorób Kobiecych AM W Poznaniu

^b Uniwersytetu Medycznego w Poznaniu   (Poland)

Author keywords

Leptin; Ovarian cancer

Indexed keywords

APOLIPOPROTEIN E; CLUSTERIN; LEPTIN; ORAL CONTRACEPTIVE AGENT;

BODY MASS; CARCINOGENESIS; CELL PROLIFERATION; ENDOMETRIOSIS; FEMALE INFERTILITY; GENE OVEREXPRESSION; GONADECTOMY; HORMONE SUBSTITUTION; HUMAN; NONHUMAN; OVARIECTOMY; OVARY CANCER; OVULATION; REVIEW;

EID: 37749015614     PISSN: 0029540X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Heintz AP, Odicino F, Maisonneuve P i wsp. Carcinoma of the ovary. In J Epidemiol Biostat FIGO 2001; 24: 115.
2. Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Review. Cancer 1993; 2 suppl. 71: 517-23.
3. Wojciechowska W, Didkowska J, Tarkowski i wsp. Nowotwory złośliwe w Polsce w roku 2003. Cancer in Poland in 2003. Warszawa: Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, 2005.
4. Hartagae PA, Whittemore AS, Itnyre J i wsp. Rates and risk of ovarian cancer in subgroups of white women in the United States. Obstet Gynecol 1994; 84: 760-4.
5. Fathalla MF. Factors in the causation and incidence of ovarian cancer. Obstet Gynecol Surv 1972; 27: 751-68.
6. Wynder E, Dodo H, Barber HRK. Epidemiology of cancer of the ovary. Cancer 1969; 23: 352-70.
7. Parazzini F, Chatenoud L, Chiantera V i wsp. Population attributable risk for ovarian cancer. Eur J Cancer 2000; 36: 520-4.
8. Venn A, Watson L, Lumley J i wsp. Breast and ovarian cancer incidence after infertility and in vitro fertilization. Lancet 1995; 346: 995-1000.
9. Bristow RE, Karlan BY. Ovulation induction, infertility and ovarian cancer risk. Fertil Steril 1966; 66: 499-507.
10. Ahima RS, Saper CB, Flier JS i wsp. Leptin regulation of neuroendocrine systems. Front Neuroendocrinol 2000; 24: 1579-83.
11. Sagava N, Yura S, Mise H i wsp. Role of leptin in pregnancy - a review. Placenta 2002; 23 suppl. A, Trophoblast Res. 16, 80-85.
12. Spicer LJ, Francisco CC. The adipose obese gene product, leptin: evidence of a direct inhibitory role in ovarian function. Endocrinology 1997; 38: 3374-9.
13. Tataranni PA, Monroe MB, Dueck CA i wsp. Adiposity, plasma leptin concentration and reproductive function in active and sedentary females. Int J Obes Relat Metab Disord 1997; 21: 818-21.
14. Stewart DE. Reproductive functions in eating disorders. Ann Med 1992; 24: 287-91.
15. Bates GW, Bates SR, Whitworth NS. Reproductive failure in women who practice weight control. Fertil and Steril 1982; 37: 373-8.
16. Carro E, Senaris RH, Seoane LM i wsp. Role of growth hormone (GH) - releasing hormone and somatostatin on leptin - induced GH secretion. Neuroendcrinology 1999; 69: 3-10.
17. Zachow BJ, Magoffin DA. Direct intraovarian effects of leptin: impairment of the synergistic action of insulin-like growth factor-I on follicle-stimulating hormone-dependent estradiol-17 beta production by rat ovarian granulosa cells. Endocrinology 1997; 128: 847-50.
18. Karlsson C, Lindell K, Svensson E i wsp. Expression of functional leptin receptors in the human ovary. J Clin Endocrinol Metab 1997; 82: 4144-84.
19. Caro JF, Kolaczyński JV, Nyce MR i wsp. Decreased cerebrospinal fluid serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996; 348: 159-161.
20. Dominguez F, Pellicer A, Simon C. Paracrine dialogue in implantation. Mol Cell Endocrinol 2002; 186: 175-81.
21. Auersperg N, Maines-Bandiera SL, Dyck HG. Ovarian carcinogenesis and the biology of ovarian surface epithelium. J Cell Physiol 1997; 173: 261-5.
22. Hutson R., Ramsdale J, Wells M. p53 protein expression in putative precursor lesion of epithelial ovarian cancer. Histopathology 1995; 27: 367-71.
23. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. Review. J Natl Cancer Inst 1999; 91: 1459-67.
24. Holschneider CH H, Berek JS. Ovarian cancer: epidemiology, biology and prognostic factors. Semin Surg Oncol 2000; 19: 3-10.
25. Cella F, Giordano G, Cordera R. Serum leptin concentration during the menstrual cycle in normal-weight women: effects of an oral triphasic estrogen-progestin medication. Eur J Endocrinol 2000; 142: 174-8.
26. Paolisso G, Rizzo MR, Mazziotti G i wsp. Lack of association between changes in plasma leptin concentration and food intake during the menstrual cycle. Eur J Clin Invest 1999; 29: 490-5.
27. Mills PY, Ziegler MG, Morrison TA. Leptin is related to epinephrine levels but not reproductive hormone levels in cycling African-American and Caucasian women. Life Sci 1998; 63: 617-23.
28. Theirmaa T, Luukkaa V, Rouru J i wsp. Correlation between circulating leptin and luteinizing hormone during the menstrual cycle in normal-weight women. Eur J Endocrinol 1998; 139: 190-4.
29. Sittisomwong T, Suneja A, Kudelka AP i wsp. Estrogen replacement therapy and ovarian cancer. Eur J Gynecol Oncol 2000; 21: 348-54.
30. Riman T, Nilsson S, Persson IR. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand 2004; 83: 783-95.
31. Anderson GL, Judd HL, Kaunitz AM i wsp. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. J Am Med Assoc 2003; 290: 1739-48.
32. Kohrt WM, Landt M, Birge SJ Jr. Serum leptin levels are reduced in response to exercise training, but not hormone replacement therapy, in older women. J Clin Endocrinol Metab 1996; 81: 3980-5.
33. Rosenbaum M, Nicolson M, Hirsch J i wsp. Effect of gender, body composition, and menopause on plasma concentrations of leptin. J Clin Endocrinol Metab 1996 81: 3424-7.
34. Di Carlo C, Tommaselli GA, Nappi C. Effects of sex steroid hormones and menopause on serum leptin concentrations. Review. Gynecol Endocrinol 2002; 16: 479-91.
35. Lazennec G. Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. Review. Cancer Lett 2006; 231: 151-7.
36. Hatch KD, Beecham JB, Blessing JA I wsp. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group Study of second-line therapy in 105 patients. Cancer 1991; 68: 269-71.
37. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II Inferences regarding pathogenesis. J Natl Cancer Inst 1983; 71: 717-21.
38. Cramer DW. Epidemiologic aspects of early menopause and ovarian cancer. Ann. N.Y Acad. Sci 1990; 592: 363-75.
39. Helzlsouer KJ, Alberg AJ, Gordon GB i wsp. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 1995; 274: 1926-30.
40. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA, Cancer J Clin 2006; 56: 69-83.
41. Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol. Biomarkers Prev 1995; 4: 447-51.
42. Makhtarulina SV, Ashrafian LA. A molecular study of chlamydia trachomatis (CT) infection and ovarian epithelial carcinoma (OEC). Int J Gynecol Cancer 2006; 16 suppl. 3. Abstr. 139.
43. Bornstein SR, Abu-Asab M, Glasow A i wsp. Immunohistochemical and ultrastructural localization of leptin and leptin receptor in human white adipose tissue and differentiating human adipose cells in primary culture. Diabetes 2000; 49: 532-8.
44. Faggioni R, Fantuzzi G, Fuller J i wsp. IL-1β mediates leptin induction during inflammation. Am J Physiol 1998; 274: R 204- R 208.
45. Sampson JA. Endometrial carcinoma of the ovary arising in endometrial tissue in that organ. Arch Surg 1925; 10: 1-72.
46. Heaps JM, Nieberg RK, Berek JS. Malignant neoplasmas arising in endometriosis. Obstet Gynecol 1990; 75: 1023-8.
47. Gonzales RR, Caballero-Campo P, Jasper M i wsp. Leptin and leptin receptor are expressed in the human endometrium and endometrial leptin secretion is regulated by the human blastocyst. J Clin Endocrinol Metab 2000; 85: 4883-8.
48. Cervero A, Horcajadas JA, Martin J i wsp. The leptin system during human endometrial receptivity and preimplantation development. J Clin Endocrinol Metab 2004; 89: 2442-51.
49. Matarese G, Alviggi C, Sanna V i wsp. Increased leptin levels in serum and peritoneal fluid of patients with pelvic endometriosis. J Clin Endocrinol Metab 2000; 85: 2483-7.
50. Mahutte NG, Matalliotakis IM, Goumenou AG i wsp. Inverse correlation between peritoneal fluid leptin concentrations and the extent of endometriosis. Hum Reprod 2003; 6: 1205-9.
51. Lima-Couy J, Cervero A, Bonilla-Musoles F i wsp. Endometrial leptin and leptin receptor expression in women with severe/moderate endometriosis. Mol Hum Reprod 2004; 10: 777-82.
52. Wu MH, Chuang PC, Chen HM i wsp. Increased leptin expression in endometriosis cells is associated with endometrial stromal cell proliferation and leptin gene up- regulation. Mol Hum Reprod 2002; 8: 456-64.
53. Tavani A, Gallus S, LaVecchia C i wsp. Aspirin and ovarian cancer: an Italian case-control study. Ann Oncol 2000; 11: 1171-3.
54. Katusic S, Beard CM, Kurland LT i wsp. Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Am J Med 1985; 78 (Suppl. 1A): 50-5.
55. Gridley G, McLaughlin JK, Ekbom A i wsp. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85: 307-11.
56. Mellemkjaer L, Linet MS, Gridley G i wsp. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996; 32A: 1753-7.
57. Munkarah AR, Uddin S, Hussain A i wsp. Aspiryn induces apoptosis in ovarian cancer cells via inhibition of Akt activity and down regulation of COX-2 expression. Int J Gynecol Cancer 2006; 16 suppl 3. Abstr. 174.
58. Nowicki M, Adamkiewicz G, Bryc W I wsp. The influence of luteinizing hormone-releasing hormone analog on serum leptin and body composition in women with solitary uterine myoma. Am J Obstet Gynecol 2002; 186: 340-4.
59. Messinis IE, Milingos SD, Alexandris E i wsp. Leptin concern trations in normal women following bilateral ovariectomy. Hum Reprod 1999; 14: 913-8.
60. Harlow BL, Hartge PA. A review of perineal talc exposure and risk of ovarian cancer Regul Toxicol Pharmacol 1995; 21: 254-60.
61. Heller DS., Gordon RE, Westhoff C I wsp. Asbestos exposure and ovarian fiber burden. Am J Ind Med 1996; 29: 435-9.
62. Huncharek M, Muscat J. Use of cosmetic talc on contraceptive diaphragms and risk of ovarian cancer: A meta-analysis of nine observational studies. Ovarian cancer: Prevention and Detection of the disease and its Recurrence. Symposium Pittsburgh 2005, abstract.
63. Sekhon M, Beehler GP, Baker J i wsp. Obesity and risk of ovarian cancer. Ovarian cancer: Prevention and Detection of the disease and its recurrence. Symposium Pittsburgh 2005, abstract.
64. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-70.
65. Shih IM, Kurman RJ. Ovarian tumorigenesis. A proposed model based on morphological and molecular genetic analysis. Review. Am J Pathol 2004; 164: 1511-8.
66. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545-8.
67. Hough CD, Cho KR, Zonderman AB i wsp. Coordinately up-regulated genes in ovarian cancer. Cancer Res 2001; 61: 3869-76.
68. Choi JK. Park SH, Leung PC I wsp. Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. J Clin Endocrinol Metab 2005; 90: 207-10.
69. Kim KT, Kim SH, Moon H. Expression of immunoreactive leptin and its receptor on the cell growth and proliferation in the ovarian cancer: A preliminary report. Int J Gynecol Cancer 2006; 16 suppl. 3, abstr 309.